FDA says Eli Lilly's Zepbound and Mounjaro are available after shortage
An injection pen for Eli Lilly's weight-loss drug Zepbound is displayed in New York City, Dec. 11, 2023. Brendan McDermid…
Biotechnology
Eli Lilly's Zepbound weight-loss drug cuts heart failure risks, study finds
An Eli Lilly & Co. Zepbound injection pen is prepared in the Brooklyn borough of New York, U.S., on Thursday,…
Biogen (BIIB) Q2 2024 Results
Biogen The company on Thursday reported second-quarter earnings and revenue, which beat estimates and raised its full-year guidance as the…
Moderna (MRNA) earnings in the second quarter of 2024
Modern On Thursday, it reported second-quarter revenue that beat expectations but cut its full-year sales outlook, citing lower expected sales…
Eisai Biogen's Leqembi Alzheimer's drug shows benefits over three years
The newly FDA-approved Alzheimer's treatment, Leqembi, will be prepared at Abington Neurological Associates in Abington, Pennsylvania on Tuesday, November 7,…
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
Pfizer (PFE) Q2 2024 Results
Kena Betancur | Corbis News | Getty Images Pfizer on Tuesday reported second-quarter revenue and adjusted earnings that beat expectations…
Merck (MRK) Q2 2024 Results
An exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on February 5, 2024. Spencer Platt |…
Biogen Eisai's Leqembi Alzheimer's drug rejected by EU regulator
European drug regulators on Friday rejected Leqembi's Alzheimer's treatment Biogen and Eisaicreating another hurdle for companies as they struggle to…
Bristol Myers Squibb (BMY) Q2 2024 Results
Bristol Myers Squibb's research and development center at Cambridge Crossing in Cambridge, Massachusetts, on December 27, 2023. Adam Glanzman |…